The preventive effect of antineoplaston AS2-1 on HCC recurrence

Oncology Reports

Volumn 10, Issue 2, 2003, Pages 391-397

  Tsuda, Hideaki ^a   Sata, Michio ^b   Kumabe, Tutomu ^b   Uchida, Masafumi ^b   Hara, Hiroshi ^b  

^a Kurume Daiichi Social Insurance Hospital   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antineoplaston AS2 1; HCC; Recurrence free interval; Survival rate

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTON AS2-1; DRUG DERIVATIVE; GLUTAMINE; PHENYLACETIC ACID DERIVATIVE;

ARTICLE; CANCER STAGING; DRUG COMBINATION; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; SURVIVAL RATE; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG COMBINATIONS; FEMALE; GLUTAMINE; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHENYLACETATES; SURVIVAL RATE;

EID: 0037810723     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.2.391     Document Type: Article

References (20)

1. Kakizaki S, Takagi H, Katakai K, et al: The natural history of untreated hepatocellular carcinoma. Int J Clin Oncol 3: 299-303, 1998. (Pubitemid 28547610)
2. The Liver Cancer Study Group of Japan: Report of 14th Follow-up Investigation on Primary Liver Cancer.
3. Burzynski SR: Antineoplastons: biochemical defense against cancer. Physiol Chem Phys 8: 275-279, 1976.
4. Tsuda H, Hara H, Eriguchi N, et al: Toxicological study on antineoplaston A10 and AS2-1 in cancer patients. Kurume Med J 42: 241-246, 1996.
5. Terasaki S, Urabe K, Kaneko S, et al: Strategy of treatment for hepatocellular carcinoma - From a standpoint of clinical medicine. Clin Gastroenterol 14: 153-161, 1999.
6. Ray RB, Steele R, Meyer K, et al: Hepatitis C virus core protein represses p21 WAF1 promoter activity. Gene 208: 331-336, 1998. (Pubitemid 28120945)
7. Ray RB, Lagging LM, Meyer K, et al: Transcriptional regulation of cellular and viral promoters by the hepatitis core protein. Virus Res 37: 209-220, 1995.
8. Buetow KH, Murray JC, Israel JL, et al: Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma. Proc Natl Acad Sci USA 86: 8852-8856, 1989. (Pubitemid 20010323)
9. Chaubert P, Gayer R, Zimmermann A, et al: Germ-line mutations of the p16 INK4(MST1) gene occur in a subset of patients with hepatocellular carcinoma. Hepatology 25: 1376-1381, 1997. (Pubitemid 27250757)
10. Nishiguchi S, Kuroki T, Nakatani S, et al: Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis c with cirrhosis. Lancet 346: 1051-1055, 1988.
11. Shibata M, Morizane T, Uchida T, et al: Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatits c infection. Lancet 351: 1773-1777, 1998. (Pubitemid 28269188)
12. Hendry LB, Muldoon TG, Burzynski SR, et al: Stereochemical modeling studies of the interaction of antineoplaston A10 with DNA. Drugs Exp Clin Res 1: 77-81, 1987. (Pubitemid 17034865)
13. Castillo M: Effect of phenylalanine and its phenyl derivatives on chick brain mevalonate 5-pyrophosphate decarboxylase. Neurochem Int 18: 171-174, 1991.
14. Samid D, Shack S and Sharman LT: Phenylacetate: a novel non-toxic inducer of tumor cell differentiaton. Cancer Res 52: 1988-1992, 1992.
15. Liau MC, Lee SS and Burzynski SR: Hypomethylation of nucleic acids: a key to the induction of terminal differentiation. Int J Exp Clin Chemother 2: 187-199, 1989. (Pubitemid 20102686)
16. Tsuda H, Sugihara S, Nishida H, et al: Inhibitory effect of the combination of antineoplaston A10 injection with a small dose of cis-diamminedichloroplatinum on cell and tumor growth of human hepatocellular carcinoma. Jpn J Cancer Res 83: 527-531. 1992.
17. Tsuda H, Iemura A, Sata M, et al: Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma. Kurume Med J 43: 137-147, 1996.
18. Lowe SW, Ruley HE, Jacks T and Housman DE: P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993. (Pubitemid 23289454)
19. Tsuda H, Sata M, Kumabe T, et al: Quick response of advanced cancer to chemoradiation therapy with antineoplastons. Oncol Rep 5: 597-600, 1998. (Pubitemid 28189310)
20. Tsuda H, Sata M, Ijuuin H, et al: A novel strategy for remission induction and maintenance in cancer therapy. Oncol Rep 9: 65-68, 2002.